Viaskin Peanut Patch Shows Promise in 4- to 7-Year-Olds With Peanut Allergy

Peanut Allergy Patch Shows Promise in Boosting Treatment Response

New data presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting suggest that a skin patch delivering tiny doses of peanut protein, known as Viaskin Peanut, may significantly improve treatment response rates in young children with peanut allergies. The findings, stemming from the phase 3 VITESSE trial, indicate that after 12 months of use, nearly 47% of children aged 4-7 using the patch responded to treatment, compared to just over 14% in the placebo group. This represents a substantial difference, offering a potential new avenue for managing this common and potentially life-threatening allergy.

The Viaskin Peanut patch (VP250; DBV Technologies) delivers 250 micrograms of peanut protein daily through the skin. This approach aims to desensitize individuals to peanut allergens without the risks associated with traditional oral immunotherapy, which involves ingesting increasing amounts of peanut protein and carries a higher risk of allergic reactions. Notably, the patch allows for continued normal activities, with “no restrictions related to exercise, illness or NSAID use,” as highlighted during the presentation by Dr. David Fleischer.

Trial Design and Key Findings

The VITESSE trial involved 654 children with peanut allergy, all aged between 4 and 7 years, and with a baseline ability to tolerate a small amount of peanut protein (100 mg or less). Participants were randomly assigned to receive either the Viaskin Peanut patch or a placebo patch for 12 months. Researchers assessed treatment response based on the eliciting dose – the amount of peanut protein a child could consume without experiencing allergic symptoms. Children with a lower initial tolerance (30 mg or less) needed to reach a dose of 300 mg or higher to be considered responders, while those with a higher initial tolerance (100 mg) needed to reach 600 mg or higher.

The study demonstrated a statistically significant difference in responder rates between the two groups. Specifically, 46.6% of children using the Viaskin Peanut patch were treatment responders, compared to 14.8% in the placebo group, resulting in a response rate difference of 31.8% (95% CI, 24.52%-39.02%). This positive outcome was consistent across several sensitivity analyses, including those excluding participants with missing data or those who underwent food challenges outside the specified timeframe.

Eliciting Dose Increases and IgE Levels

Beyond responder rates, the study similarly examined changes in eliciting doses. A substantial majority – 82.8% – of children using the Viaskin Peanut patch experienced an increase of at least two eliciting doses, or one dose, by the end of the 12-month treatment period. This was significantly higher than the 47.9% observed in the placebo group.

Researchers also noted differences in baseline peanut-specific IgE levels, a measure of allergic sensitivity. Children receiving the Viaskin Peanut patch had lower mean IgE levels at the start of the trial (130.7 kUA/L) compared to those receiving the placebo (153.4 kUA/L). Baseline skin prick test results were comparable between the groups, with a median wheal diameter of 11 mm in both.

Safety Profile and Adverse Events

The Viaskin Peanut patch generally demonstrated a favorable safety profile. Most adverse events reported were mild to moderate local application-site reactions. Severe or serious adverse events were rare, occurring in only 1.1% and 1.4% of the Viaskin Peanut patch group, respectively. A small percentage of children (3.2%) discontinued treatment due to adverse events, compared to 0.5% in the placebo group. Two children in the Viaskin group experienced treatment-related anaphylaxis, but continued treatment after receiving appropriate medical care, as previously reported in a press release. Topline results from VITESSE were initially reported in January.

What So for Peanut Allergy Management

Peanut allergy affects millions of children worldwide, and current management strategies primarily focus on strict avoidance of peanuts. While effective in preventing reactions, avoidance can be challenging and negatively impact quality of life. Oral immunotherapy is an emerging treatment option, but it requires careful monitoring and carries the risk of severe allergic reactions. The Viaskin Peanut patch offers a potentially safer and more convenient approach to desensitization.

“You desire things that are practical and easy to use for patients and safe and effective as well, and I consider this product meets these requirements,” stated Dr. Fleischer. The patch’s ease of use – a daily application at home – and lack of restrictions on activity could develop it a more accessible treatment option for many families. Although, it’s crucial to remember that this is not a cure for peanut allergy. The goal of treatment is to increase the threshold at which a reaction occurs, reducing the risk of accidental reactions and improving overall quality of life.

Understanding IgE and Eliciting Doses

Peanut-specific IgE levels are a measure of the antibodies the body produces in response to peanut proteins. Higher levels generally indicate a greater degree of allergic sensitivity. However, IgE levels alone don’t always predict the severity of a reaction. The eliciting dose, provides a more direct measure of a person’s tolerance to peanut protein. Increasing the eliciting dose through desensitization therapies like the Viaskin Peanut patch aims to reduce the risk of reactions to accidental peanut exposure. The American Academy of Allergy, Asthma & Immunology provides further information on peanut allergy and its management.

Next Steps and Future Research

The VITESSE trial data are encouraging, and the researchers are continuing to follow participants in an open-label extension study to assess the long-term effects of the Viaskin Peanut patch. Further research is needed to determine the optimal duration of treatment and to identify which patients are most likely to benefit. The data will also be reviewed by regulatory agencies, such as the Food and Drug Administration (FDA) in the United States, to determine whether to approve the patch for clinical use. The FDA website provides information on the drug approval process.